Home/Filings/4/0001213900-24-077791
4//SEC Filing

Kelly Paul Edward 4

Accession 0001213900-24-077791

CIK 0001553643other

Filed

Sep 10, 8:00 PM ET

Accepted

Sep 11, 5:46 PM ET

Size

5.3 KB

Accession

0001213900-24-077791

Insider Transaction Report

Form 4
Period: 2024-09-09
Kelly Paul Edward
DirectorChief Operating Officer
Transactions
  • Purchase

    Common Stock

    2024-09-09$2.59/sh+25,000$64,750212,295 total
Footnotes (2)
  • [F1]The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range.
  • [F2]Purchase prices range from $2.50 to $2.64 per share, inclusive.

Documents

1 file

Issuer

RELMADA THERAPEUTICS, INC.

CIK 0001553643

Entity typeother

Related Parties

1
  • filerCIK 0001658544

Filing Metadata

Form type
4
Filed
Sep 10, 8:00 PM ET
Accepted
Sep 11, 5:46 PM ET
Size
5.3 KB